Get started
Author

Andrzej Marek Kukiełka

Observed names: A. Kukielka, A. Kukiełka, A. M. Kukiełka, A.M. Kukiełka, Andrzej Kukielka, Andrzej Kukiełka, Andrzej M. Kukielka, Andrzej M. Kukiełka, Kukiełka, Andrzej Marek
ORCID: 0000-0001-9940-0204
Observed ORCID: 0000-0001-9940-0204
OpenAlex ID: A5004512883
Quality assurance guidelines for interstitial hyperthermia
2019 · H. Dobšíček Trefná, M. Schmidt, et al. · International Journal of Hyperthermia · 66
PDF
High-dose-rate brachytherapy as a monotherapy for prostate cancer—Single-institution results of the extreme fractionation regimen
2015 · Andrzej Marek Kukiełka, Tomasz Dąbrowski, et al. · Brachytherapy · 35
Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure
2013 · A.M. Kukiełka, M. Hetnał, et al. · Strahlentherapie und Onkologie · 35
Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study
2023 · Mark T. Corkum, Mark K. Buyyounouski, et al. · Radiotherapy and Oncology · 32
PDF
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases
2024 · Mateusz J Swierz, Dawid Storman, et al. · Cochrane Database of Systematic Reviews · 12
PDF
Interstitial hyperthermia of the prostate in combination with brachytherapy: An evaluation of feasibility and early tolerance
2013 · A.M. Kukiełka, M. Hetnał, et al. · Strahlentherapie und Onkologie · 11
Educational article Salvage brachytherapy in combination with interstitial hyperthermia for locally recurrent prostate carcinoma following external beam radiation therapy: a prospective phase II study
2015 · Andrzej M. Kukiełka, Vratislav Strnad, et al. · Journal of Contemporary Brachytherapy · 10
PDF
Evaluation of tolerance and toxicity of high-dose-rate brachytherapy boost combined with interstitial hyperthermia for prostate cancer
2016 · Andrzej Marek Kukiełka, Marcin Hetnał, et al. · International Journal of Hyperthermia · 9
PDF
Does microwave interstitial hyperthermia prior to high-dose-rate brachytherapy change prostate volume or therapy plan parameters?
2015 · Roksana Kudzia, Damian Nahajowski, et al. · International Journal of Hyperthermia · 6
PDF
Half body irradiation (HBI) for bone metastases in the modern radiotherapy technique era – A systematic review
2024 · Mateusz Bilski, Katarzyna Konat-Bąska, et al. · Clinical and Translational Radiation Oncology · 5
PDF
Transarterial (chemo)embolisation versus chemotherapy for colorectal cancer liver metastases
2017 · Malgorzata M Bala, Jerzy W. Mituś, et al. · Cochrane Database of Systematic Reviews · 5
Prospective Phase 2 Trial: Long-term results of a salvage brachytherapy combined with interstitial hyperthermia as Re-Irradiation for locally recurrent prostate Carcinoma
2026 · Vratislav Strnad, Mateusz Dąbkowski, et al. · Radiotherapy and Oncology · 3
PDF
Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer
2026 · Artur J. Chyrek, Marcin Hetnał, et al. · Journal of Contemporary Brachytherapy · 3
PDF
MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) – A propensity score matched analysis
2025 · Mateusz Bilski, Piotr Lelek, et al. · Radiotherapy and Oncology · 3
PDF
Role of irradiation in combined treatment of head and neck paragangliomas at the Centre of Oncology in Krakow between 1970–2005
2014 · Magdalena Pęcak, Elżbieta Pluta, et al. · Współczesna Onkologia · 2
PDF
Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment: a multicenter study integrating urodynamics and patient-reported outcomes
2026 · Krzysztof Bereza, Andrzej Kukiełka, et al. · Frontiers in Oncology · 1
PDF
Outcomes of Radiotherapy With or Without Dose Escalation to Lymph Node Metastases Detected by PET PSMA or Conventional Imaging in Node-Positive Prostate Cancer: A Real-World Multicenter Propensity Score-Matched (PRIMENOD) Analysis
2026 · Mateusz Bilski, Federico Mastroleo, et al. · Clinical Nuclear Medicine · 1
PPP01 Presentation Time: 9:30 AM
2026 · Vratislav Strnad, Mateusz Dąbkowski, et al. · Brachytherapy
Molecular Determinants of Treatment Resistance in Cervical Cancer: A Systematic Review and Integrative Bioinformatic Analysis of Publicly Available Datasets
2026 · Krzysztof Bereza, Andrzej Kukiełka, et al. · Medical Science Monitor
PDF
Correction: Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment: a multicenter study integrating urodynamics and patient-reported outcomes
2026 · Krzysztof Bereza, Andrzej Kukiełka, et al. · Frontiers in Oncology
PDF
3658 Real-world oncological outcomes of metastasisdirected therapy for synchronous oligometastatic prostate cancer: propensity score-matched analysis
2026 · Magdalena Stankiewicz, Mateusz Bilski, et al. · Radiotherapy and Oncology
Real-world oncological outcomes and toxicity of metastasis-directed therapy for synchronous oligometastatic prostate cancer (ATTENTION)
2025 · M. Stankiewicz, M. Bilski, et al. · European Urology Open Science
Tailoring Nodal Radiotherapy in regionally advanced prostate cancer: A multicenter study of dose escalation outcomes based on PSMA PET vs. conventional imaging
2025 · M. Bilski, F. Mastroleo, et al. · European Urology Open Science
Multicentre retrospective comparison of definitive EBRT with or without HDR brachytherapy boost in patients with locally-advanced prostate cancer and regional lymph node metastases – a propensity score matched analysis
2025 · M. Bilski, P. Lelek, et al. · European Urology Open Science
PP02 Presentation Time: 9:10 AM
2022 · Mark T. Corkum, Mark Buyyounouski, et al. · Brachytherapy
Works count: 35
Citation count: 239
H-index: 8
I10-index: 7
Year
Topic
Type